SSRI Discontinuation After One Year
Gradually taper the SSRI over several weeks rather than stopping abruptly to prevent discontinuation syndrome, which can cause significant distressing symptoms. 1
Why Gradual Tapering is Essential
Never stop SSRIs abruptly. 1 The discontinuation syndrome is a well-established clinical entity that occurs when SSRIs are stopped suddenly or tapered too quickly. 2, 3
Discontinuation Syndrome Characteristics
The syndrome typically includes:
- Somatic symptoms: dizziness, nausea, fatigue, lethargy, myalgias, chills, headaches, sensory disturbances, paresthesias 2, 3
- Psychological symptoms: anxiety, irritability, agitation, crying spells 3
- Onset: Usually within 1 week of stopping treatment 4
- Duration: Generally resolves spontaneously within 3 weeks if left untreated 4
- Resolution: Symptoms resolve within 48 hours if the SSRI is reinstituted 4
Tapering Strategy
Taper all SSRIs gradually except fluoxetine, which has an extended half-life and may not require tapering. 3
Drug-Specific Considerations
- Paroxetine, fluvoxamine, and sertraline have the highest risk of discontinuation syndrome and require the most cautious tapering 2, 1
- Shorter half-life SSRIs (venlafaxine, fluvoxamine, paroxetine) should be tapered especially gradually 3
- Fluoxetine may not require tapering due to its long half-life 3
Practical Tapering Approach
- Reduce the dose incrementally over several weeks 3, 5
- Monitor closely during the taper for emergence of discontinuation symptoms 5
- If symptoms emerge during taper: slow the rate of taper or temporarily return to the previous dose 3
- Educate the patient about potential discontinuation symptoms so they are not mistaken for relapse or physical illness 3, 6
Clinical Pitfalls to Avoid
Do not mistake discontinuation symptoms for relapse of the original psychiatric condition or new physical illness. 3, 6 This misdiagnosis can lead to unnecessary testing, inappropriate treatment, and increased healthcare costs. 3
Ensure medication continuity from the pharmacy - generic drugs can vary up to 20% in bioequivalence, and switching manufacturers during tapering can precipitate discontinuation symptoms. 5
When to Consider Continuing Treatment
The decision to discontinue should be an active one involving both patient and prescriber. 7 Consider:
- Risk of relapse: The major benefit of long-term SSRI use is relapse prevention 7
- Duration of remission: Patients stable for one year may be candidates for discontinuation, but this should be weighed against relapse risk 7
- Patient preference and quality of life 7
If Discontinuation Symptoms Occur
Reinstitute the original SSRI at the previous dose - this provides rapid symptom relief within 48 hours. 4 Then restart a slower taper. 3